Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China

References

• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392. doi:10.1016/S1473-3099(17)30316-X28774698
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, LassFlörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(Suppl 2):2–13. doi:10.1111/myc.12330
   PubMed Web of Science ®Google Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10. doi:10.1111/1469-0691.12539
   Web of Science ®Google Scholar
• Xiao M, Fan X, Chen CA, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in china: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802–810. doi:10.1093/jac/dku46025473027
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(11):e954–e966. doi:10.1016/j.ijid.2010.04.00620797887
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39(9):3254–3259.11526159
   PubMed Web of Science ®Google Scholar
• Schwartz IS, Patterson TF. The emerging threat of antifungal resistance in transplant infectious diseases. Curr Infect Dis Rep. 2018;20(3):2. doi:10.1007/s11908-018-0608-y29404711
   PubMed Web of Science ®Google Scholar
• Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 national China Hospital Invasive Fungal Surveillance Net (CHIFNET) study. J Clin Microbiol. 2012;50:3952–3959. doi:10.1128/JCM.01263-1123035204
   PubMed Web of Science ®Google Scholar
• Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother. 2005;49(2):783–787. doi:10.1128/AAC.49.2.783-787.200515673768
   PubMed Web of Science ®Google Scholar
• Redding SW, Kirkpatrick WR, Saville S, et al. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003;41(2):619–622.12574256
   PubMed Web of Science ®Google Scholar
• Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother. 2004;48(5):1773–1777.15105134
   PubMed Web of Science ®Google Scholar
• Torelli R, Posteraro B, Ferrari S, et al. The ATP‐binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1‐dependent azole resistance of Candida glabrata. Mol Microbiol. 2008;68(1):186–201. doi:10.1111/j.1365-2958.2008.06143.x18312269
   PubMed Web of Science ®Google Scholar
• Vermitsky JP, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome‐wide expression studies. Mol Microbiol. 2006;61(3):704–722. doi:10.1111/j.1365-2958.2006.05235.x16803598
   PubMed Web of Science ®Google Scholar
• Vermitsky JP, Edlind TD. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother. 2004;48(10):3773–3781. doi:10.1128/AAC.48.10.3773-3781.200415388433
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Miyazaki Y, Geber A, et al. Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother. 1998;42(7):1695–1701.9661006
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992;36(12):2602–2610.1482129
   PubMed Web of Science ®Google Scholar
• Li F, Wu L, Cao B, Zhang Y, Li X, Liu Y. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13(1):353. doi:10.1186/1471-2334-13-35323899244
   PubMed Web of Science ®Google Scholar
• Chen PL, Lo HJ, Wu CJ, et al. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999–2006. Mycoses. 2011;54(4):e17–23. doi:10.1111/j.1439-0507.2009.01818.x20028463
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th Wayne, PA: Clinical and Laboratory Standards Institute; 2017
   Google Scholar
• Maesaki S, Marichal P, Vanden Bossche H, Sanglard D, Kohno S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother. 1999;44(1):27–31.10459807
   PubMed Web of Science ®Google Scholar
• Peng Y, Dong D, Jiang C, Yu B, Wang X, Ji Y. Relationship between respiration deficiency and azole resistance in clinical, Candida glabrata. FEMS Yeast Res. 2012;12(6):719–727. doi:10.1111/j.1567-1364.2012.00821.x22713096
   PubMed Web of Science ®Google Scholar
• Jiang C, Dong D, Yu B, et al. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother. 2013;68(4):778–785. doi:10.1093/jac/dks48123221625
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Brun S, Bergès T, Poupard P, et al. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother. 2004;48(5):1788–1796.15105136
   PubMed Web of Science ®Google Scholar
• Ferrari S, Ischer F, Calabrese D, et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 2009;5(1):e1000268. doi:10.1371/journal.ppat.100070619148266
   PubMed Web of Science ®Google Scholar
• Lewis JS, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother. 2013;57(9):4559–4561. doi:10.1128/AAC.01144-1323817368
   PubMedGoogle Scholar
• Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl 3):S445–S451. doi:10.1093/infdis/jix13128911043
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199–1203. doi:10.1128/JCM.01263-1122278842
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51(8):2571–2581. doi:10.1128/JCM.00308-1323720791
   PubMed Web of Science ®Google Scholar
• Xin H, Meng X, Chen SCA, et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (august 2009 to July 2014): a Multi-center study. Front Microbiol. 2017;8:880. doi:10.3389/fmicb.2017.0088028588560
   PubMed Web of Science ®Google Scholar
• Hou X, Xiao M, Wang H, et al. Profiling of PDR1 and MSH2 in Candida glabrata bloodstream isolates from a multi-center study in China. Antimicrob Agents Chemother. 2018;62(6):e00153–18. doi:10.1128/AAC.00153-1829581110
   PubMed Web of Science ®Google Scholar
• Yao D, Ying C, Zheng B. Application evaluation of microsatellite polymorphism and multilocus sequence typing in genotyping of Candida glabrata. Lab Med. 2014;29(6):593–596.
   Google Scholar
• Zheng B, Yao D, Ying C, Wang Y, Zhang H, Yang J. Epidemiology and drug-resistance analysis of nosocomial infection of Candida glabrata. Lab Med. 2012;27(6):461–466.
   Google Scholar
• Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D, Cramer R. Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One. 2011;6(3):e17589. doi:10.1371/journal.pone.001758921408004
   PubMed Web of Science ®Google Scholar
• Ferrari S, Sanguinetti M, De Bernardis F, et al. Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother. 2011;55(5):1852–1860. doi:10.1128/AAC.01271-1021321146
   PubMed Web of Science ®Google Scholar
• Shin JH, Chae MJ, Song JW, et al. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol. 2007;45(8):2389–2391. doi:10.1128/JCM.00381-07
   Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Trecarichi EM, et al. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother. 2008;62(6):1379–1385. doi:10.1093/jac/dkn38118782778
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668–679. doi:10.1128/AAC.49.2.668-679.200515673750
   PubMed Web of Science ®Google Scholar
• Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2000;44(10):2693–2700.d10991846
   PubMed Web of Science ®Google Scholar
• Niimi M, Nagai Y, Niimi K, et al. Identification of two proteins induced by exposure of the pathogenic fungus Candida glabrata to fluconazole. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;782(1–2):245–252.
   Web of Science ®Google Scholar
• Samaranayake YH, Cheung BPK, Wang Y, Yau JY, Yeung KW, Samaranayake LP. Fluconazole resistance in Candida glabrata is associated with increased bud formation and metallothionein production. J Med Microbiol. 2013;62(Pt 2):303–318. doi:10.1099/jmm.0.044123-023002065
   PubMed Web of Science ®Google Scholar
• Shen Y, Lu H, Zhang Y. Analysis of ERG11 gene mutations in fluconazole-resistant Candida glabrata strains. Chin J Infect Dis. 2010;6(28):331–335.
   Google Scholar
• Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD. Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell. 2011;10(3):373–383. doi:10.1128/EC.00073-1021193550
   PubMedGoogle Scholar
• Tsai HF, Sammons LR, Zhang X, et al. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother. 2010;54(8):3308–3317. doi:10.1128/AAC.00535-1020547810
   PubMed Web of Science ®Google Scholar